Clinical Trial Update: A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Unresectable Advanced and/or Metastatic Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating first-line erlotinib (Tarceva) in combination with gemcitabine for unresectable advanced/metastatic non-small cell lung cancer; results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Tarceva (erlotinib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-small Cell Lung Cancer Metastatic | Phase 2 | Status: COMPLETED | Results posted: 2016-05-19